Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$7.21 – $21.41
65% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $30.8K | $75.0K | $0 | $0 | $0 | $1.4M |
| Cost of revenue | $0 | $0 | $964.2K | $0 | $0 | $0 | $0 | $180.6K |
| Gross profit | $0 | $0 | −$933.5K | $75.0K | $0 | $0 | $0 | $1.2M |
| Gross margin | — | — | -3034.5% | 100.0% | — | — | — | 86.7% |
| R&D | $0 | $0 | $3.5K | $0 | $20.9K | $6.7M | $2.3M | $1.3M |
| Operating income | $0 | $0 | −$6.9M | −$14.0M | −$34.2M | −$21.5M | −$10.1M | −$13.0M |
| EBITDA | −$7.1K | $171.9K | −$8.7M | −$12.8M | −$36.4M | −$20.1M | −$9.4M | −$10.4M |
| Net income | −$7.1K | −$2.2K | −$9.2M | −$13.4M | −$37.6M | −$21.3M | −$10.7M | −$11.9M |
| Net margin | — | — | -29765.9% | -17932.4% | — | — | — | -874.3% |
| EPS (diluted) | -0.01 | -0.00 | -0.45 | -13.16 | -2.87 | -0.83 | -5.65 | -2.81 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1M | $-3.40 | $-3.40–$-3.40 | 1 |
| 2027 | $766712 | $-3.60 | $-3.60–$-3.60 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds COEP.
No tracked institution reports a position in COEP as of their last filing.
| Execution date | Ratio |
|---|---|
| 2024-12-31 | 1-for-20reverse |
| 2020-08-06 | 200-for-1 |
| 2020-08-06 | 1-for-40000reverse |
No one on the platform has traded COEP yet.
| $229M |
| — |
| MDCXMedicus Pharma Ltd. Common Stock | $0.49 | +6.51% | $11M | — |
| NRXPNRx Pharmaceuticals, Inc. | $4.00 | +7.24% | $69M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.